Watch CODX. Know when insiders buy.
One email the day a filing lands. Free.
CODX
Co-Diagnostics, Inc.
0.62
−0.03 −4.23%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.9MP/E —DIV YIELD —FCF YIELD -709.11%REV TTM $721K −28.1%NET INCOME −$47.1MNET CASH $3.4M52W 0.62 – 37.80SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $166K | +2.0% | 72.7% | −$6.2M | −$6.3M | — | -1.46 | −$7.2M | $18K | −$7.2M | Aug 13 |
| Q1 2026 · Mar 31 | $146K | +190.3% | -32.8% | −$9.2M | −$9.1M | — | -4.06 | −$7.8M | $142K | −$8M | Aug 13 |
| Q4 2025 · Dec 31derived | $264K | +76.7% | 46.0% | −$26.5M | −$25.7M | — | -34.63 | −$6.2M | $132K | −$6.3M | Mar 31 |
| Q3 2025 · Sep 30 | $145K | −77.3% | 81.9% | −$7M | −$5.9M | — | -0.16 | −$5.9M | $75K | −$6M | Nov 13 |
| Q2 2025 · Jun 30 | $163K | −93.9% | 80.3% | −$8.1M | −$7.7M | — | -7.00 | −$8.3M | $401K | −$8.7M | Aug 13 |
| Q1 2025 · Mar 31 | $50K | −89.3% | 57.1% | −$8.6M | −$7.5M | — | -7.05 | −$8.7M | $92K | −$8.8M | Aug 13 |
| Q4 2024 · Dec 31derived | $149K | −95.8% | -70.8% | −$11.9M | −$11M | — | -36.34 | −$8.2M | $73K | −$8.3M | Mar 31 |
| Q3 2024 · Sep 30 | $641K | −73.9% | 53.6% | −$10.2M | −$9.7M | — | -0.32 | −$7.2M | $174K | −$7.4M | Nov 13 |
| Q2 2024 · Jun 30 | $2.7M | — | 92.0% | −$7.7M | −$7.6M | — | -0.25 | −$5.2M | $99K | −$5.3M | Nov 13 |
| Q1 2024 · Mar 31 | $468K | — | 49.9% | −$10.3M | −$9.3M | — | -0.31 | −$8.5M | $402K | −$8.9M | Nov 13 |
| Q4 2023 · Dec 31derived | $3.6M | — | 16.5% | −$11.8M | −$14.7M | — | -0.50 | −$4.8M | $465K | −$5.2M | Mar 27 |
| Q3 2023 · Sep 30 | $2.5M | — | 89.6% | −$8.9M | −$6M | — | -0.20 | −$5.8M | $237K | −$6M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $622K | 64.3% | −$50.2M | −$46.9M | -7533.6% | -35.25 | −$29.1M | $700K | −$29.8M | — | — |
| FY2024 · to Dec 31 | $3.9M | 74.5% | −$40.1M | −$37.6M | -961.4% | -37.22 | −$29.2M | $748K | −$29.9M | — | — |
| FY2023 · to Dec 31 | $6.8M | 38.6% | −$42.7M | −$35.3M | -518.7% | -1.20 | −$22.1M | $1.4M | −$23.4M | $1.4M | — |
| FY2022 · to Dec 31 | $34.2M | 84.0% | −$27M | −$14.2M | -41.6% | -0.45 | $6.6M | $1.4M | $5.1M | $14.2M | — |
| FY2021 · to Dec 31 | $97.9M | 88.2% | $46.1M | $36.7M | 37.5% | 1.23 | $41.1M | $669K | $40.4M | — | — |
| FY2020 · to Dec 31 | $74.6M | 77.7% | $41.7M | $42.5M | 57.0% | 1.52 | $28.2M | $774K | $27.4M | — | — |
Every number comes from Co-Diagnostics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.